TriangleFOR PATIENTS · SOURCE READING
Treatment of High-Risk LCH in Children
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 6, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
For information about the treatments listed below, see the Treatment Option Overview section.
Source links and citations
Treatment of newly diagnosed childhood LCH multisystem disease lesions in the spleen, liver, or bone marrow and another organ or site may include:
Chemotherapy and steroid therapy. Higher doses of more than one chemotherapy drug and steroid therapy may be given to patients whose tumors do not respond to initial chemotherapy.
Source links and citations
Targeted therapy (vemurafenib).
Source links and citations
A liver transplant for patients with severe liver damage.
Source links and citations
A clinical trial that tailors the patient's treatment based on features of the LCH at diagnosis and how it responds to treatment.
A clinical trial of chemotherapy and steroid therapy.
Preserved source evidence · Independent clinical review pending · Not medical advice